Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
朗盛投资集团有限公司, founded in 2010 and headquartered in China, manages a fund size of $190 million. The firm has grown its assets under management from 66 million yuan to over 1.3 billion yuan, overseeing more than 40 investment cases. It focuses on developing industry-leading companies in the healthcare sector.
朗盛投资 specializes in early-stage investments in the healthcare sector, particularly in biopharmaceuticals, biotechnology, medical devices, and healthcare services. The firm primarily invests in angel and Series A rounds, with a strong emphasis on projects within the Chinese market.
Notable portfolio companies include 安翰科技, which developed the world's first actively controlled capsule endoscope robot, and 莱馥生命科技, focusing on stem cell storage and cell therapy technologies. Other investments include 博奥晶典 for next-generation biological detection, 艾比玛特 for proteomics research platforms, and 国药健康在线, an e-commerce platform for pharmaceuticals.
Submit your pitch through their website's contact form for consideration.
朗盛投资 often leads rounds, particularly in angel and Series A financing stages, where they can provide significant support and guidance to early-stage companies.
The firm is open to follow-on investments, especially for companies that demonstrate strong growth potential and align with their healthcare focus.
朗盛投资 currently manages a fund size of $190 million, allowing them to make substantial investments in promising healthcare startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.